This association has been interpreted as indicating that high CD133 expression signature levels are associated with more advanced tumors because somatic mutations accumulate during cancer progression [16]; however, the association of high CD133 expression levels in low tumor stages in our study suggested that the activity of CD133 may arise early in cancer development [31]. This evidence concerns the gene PROM1 and neoplasm.